Financial Services -
Asset Management - NYSE - US
$ 18.14
0.847 %
$ 3.18 B
Market Cap
13.44
P/E
1. INTRINSIC VALUE
Balance Sheet
Hercules Capital, Inc.
| Current Assets | 75.3 M |
| Cash & Short-Term Investments | 42.7 M |
| Receivables | 32.6 M |
| Other Current Assets | 0 |
| Non-Current Assets | 16.8 M |
| Long-Term Investments | 0 |
| PP&E | 16.8 M |
| Other Non-Current Assets | 0 |
| Current Liabilities | 54.9 M |
| Accounts Payable | 54.9 M |
| Short-Term Debt | 0 |
| Other Current Liabilities | 0 |
| Non-Current Liabilities | 1.82 B |
| Long-Term Debt | 0 |
| Other Non-Current Liabilities | 1.82 B |
EFFICIENCY
Earnings Waterfall
Hercules Capital, Inc.
| Revenue | 416 M |
| Cost Of Revenue | 54.2 M |
| Gross Profit | 362 M |
| Operating Expenses | 124 M |
| Operating Income | 237 M |
| Other Expenses | 206 M |
| Net Income | 31.5 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Hercules Capital, Inc.
| Net Income | 31.5 M |
| Depreciation & Amortization | 466 K |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 0 |
| Change in Working Capital | 15.4 M |
| Others | -150 M |
| Free Cash Flow | -118 M |
Wall Street Analysts Price Targets
Hercules Capital, Inc.
Wall Street analysts predict an average 1-year price target for HTGC of $19.9 , with forecasts ranging from
a
low of
$13 to a high of $22 .
HTGC Lowest Price Target
Wall Street Target
13 USD
-28.34%
HTGC Average Price Target
Wall Street Target
19.9 USD
9.86%
HTGC Highest Price Target
Wall Street Target
22 USD
21.28%
4. DIVIDEND
ANALYSIS
2.45%
DIVIDEND YIELD
0.47 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Hercules Capital, Inc.
Sold
0-3 MONTHS
7.04 K USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
1.96 M USD 1
9-12 MONTHS
295 K USD 1
Bought
563 K USD 7
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
514 K USD 6
9-12 MONTHS
7. News
Warning To All BDC Investors
I am increasingly cautious on BDCs due to rising non-accruals, weaker earnings, and looser underwriting amid intense competition for private credit deals. Elevated interest rates are suppressing BDC valuations and making it harder for borrowers to service debt, leading to fewer quality investment opportunities. Dividend coverage is weakening across many BDCs, with higher non-accruals and PIK income threatening the sustainability of distributions investors rely on.
seekingalpha.com
- 2 weeks ago
3 Strong Buy Stocks Yielding at Least 9% That Have Huge Upside Potential
Do you need to generate more passive income from your stock holdings? Schedule a meeting with a financial advisor near you for a complete portfolio review.
247wallst.com
- 3 weeks ago
Buy Any Of 18 Ideal 'Safer' May Dividend Dogs Out Of 70 Graham Value All-Stars (GVAS)
I use YCharts' Value Score and Ben Graham Formula to identify large-cap stocks offering strong value relative to profits, assets, and dividends. Eighteen of twenty-four 'safer' lowest-priced Dividend Dogs of the GVAS are fair-priced and ready to buy for income-focused investors. Top ten GVAS stocks are projected to deliver 17.99% to 68.74% net gains by May 2026, with average risk 29% below the market.
seekingalpha.com
- 4 weeks ago
ARCC vs. HTGC: Which BDC Has More Upside Amid Market Uncertainty?
Can tech-focused Hercules Capital outperform diversified Ares Capital in today's uncertain market? Let's find out.
zacks.com
- 4 weeks ago
Hercules Capital: Contrarian Buying Opportunity
Hercules Capital delivered decent Q1 results, with robust net investment income supporting its attractive dividend yield. The investment firm maintained excellent balance sheet quality, reinforcing confidence in its dividend sustainability. Despite trading at a 56% premium to NAV, I believe the premium is justified by Hercules Capital's consistent dividend coverage and growth in portfolio investments.
seekingalpha.com
- 1 month ago
Hercules Capital: A Strong BDC Investment Pick (Rating Upgrade)
Hercules Capital is a top BDC choice for passive income investors, offering solid dividends supplemented by non-base distributions and strong credit quality. The BDC focuses on the technology sector, with a portfolio value of $3.9 billion and a low non-accrual ratio of 0.5%. Despite a premium valuation, Hercules Capital's consistent performance, high net investment income, and supplemental dividends justify its 'Strong Buy' rating.
seekingalpha.com
- 1 month ago
Altimmune Secures Up to $100 Million in Credit Facility from Hercules Capital
GAITHERSBURG, Md., May 13, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that it has entered into an agreement with Hercules Capital, Inc. (NYSE: HTGC), a leader in debt financing for life science companies, for up to $100 million in a credit facility, with a $15 million tranche funded at closing.
globenewswire.com
- 1 month ago
BDC Weekly Review: Bimodal Q1 Numbers Weigh On The Sector
We take a look at the action in business development companies through the first week of May and highlight some of the key themes we are watching. BDCs fell around 1.5% this week due to a couple of weak Q1 reports, with the sector still below pre-Liberation Day levels. Despite recent dips, historically resilient BDCs are showing strong ROE figures, suggesting selective opportunities for patient investors.
seekingalpha.com
- 1 month ago
Dividend Investors, It's Time To Raise Cash, Here's Why
Despite my usual inclination to invest in dividend-paying stocks, current market valuations and economic risks lead me to prefer raising cash over investing. The 10-year Treasury yield reflects a tug-of-war between inflation and economic weakness, influenced by tariffs and trade uncertainties. The recent U.S.-U.K. trade deal is a positive development, but it doesn't fully offset the higher tariffs still in place post-"Liberation Day."
seekingalpha.com
- 1 month ago
2 BDCs On My Recession Radar
BDCs, previously top performers due to high yields and rising rates, now face selling pressure amid economic uncertainty and potential interest rate cuts. Hercules Capital and Trinity Capital, despite solid fundamentals, may see tighter dividend coverage and selling pressure if rates decline as expected. Both BDCs have strong balance sheets and spillover income, ensuring near-term dividend safety despite potential economic headwinds.
seekingalpha.com
- 1 month ago
Hercules Capital Announces Date of 2025 Annual Meeting of Stockholders
SAN MATEO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”), will conduct its 2025 Annual Meeting of Stockholders by virtual meeting on Wednesday, June 18, 2025 at 9:00 a.m. (Eastern Time). The proxy statement for the meeting was filed on April 24, 2025 and mailed to stockholders of record as of April 17, 2025. 2025 Annual Meeting of Stockholders June 18, 2025 at 9:00 a.m. Eastern Time Virtual Meeting via Internet: http://www.virtualshareholdermeeting.c.
businesswire.com
- 1 month ago
HTGC's Q1 Earnings Lag Estimates, Total Investment Income Dips
Hercules Capital's first-quarter 2025 earnings narrowly miss estimates due to a dip in total investment income amid a modest rise in expenses.
zacks.com
- 1 month ago
8. Profile
Summary
Hercules Capital, Inc. HTGC
COUNTRY
US
INDUSTRY
Asset Management
MARKET CAP
$ 3.18 B
Dividend Yield
2.45%
Description
Hercules Capital, Inc. is a business development company. The firm specializing in providing venture debt, debt, senior secured loans, and growth capital to privately held venture capital-backed companies at all stages of development from startups, to expansion stage including select publicly listed companies and select special opportunity lower middle market companies that require additional capital to fund acquisitions, recapitalizations and refinancing and established-stage companies. The firm provides growth capital financing solutions for capital extension; management buy-out and corporate spin-out financing solutions; company, asset specific, or intellectual property acquisition financing; convertible, subordinated and/or mezzanine loans; domestic and international corporate expansion; vendor financing; revenue acceleration by sales and marketing development, and manufacturing expansion. It provides asset-based financing with a focus on cash flow; accounts receivable facilities; equipment loans or leases; equipment acquisition; facilities build-out and/or expansion; working capital revolving lines of credit; inventory. The firm also provides bridge financing to IPO or mergers and acquisitions or technology acquisition; dividend recapitalizations and other sources of investor liquidity; cash flow financing to protect against share price volatility; competitor acquisition; pre-IPO financing for extra cash on the balance sheet; public company financing to continue asset growth and production capacity; short-term bridge financing; and strategic and intellectual property acquisition financings. It also focuses on customized financing solutions, emerging growth, mid venture, and late venture financing. The firm invests primarily in structured debt with warrants and, to a lesser extent, in senior debt and equity investments. The firm generally seeks to invest in companies that have been operating for at least six to 12 months prior to the date of their investment. It prefers to invest in technology, energy technology, sustainable and renewable technology, and life sciences. Within technology the firm focuses on advanced specialty materials and chemicals; communication and networking, consumer and business products; consumer products and services, digital media and consumer internet; electronics and computer hardware; enterprise software and services; gaming; healthcare services; information services; business services; media, content and information; mobile; resource management; security software; semiconductors; semiconductors and hardware; and software sector. Within energy technology, it invests in agriculture; clean technology; energy and renewable technology, fuels and power technology; geothermal; smart grid and energy efficiency and monitoring technologies; solar; and wind. Within life sciences, the firm invests in biopharmaceuticals; biotechnology tools; diagnostics; drug discovery, development and delivery; medical devices and equipment; surgical devices; therapeutics; pharma services; and specialty pharmaceuticals. It also invests in educational services. The firm invests primarily in United States based companies and considers investment in the West Coast, Mid-Atlantic regions, Southeast and Midwest; particularly in the areas of software, biotech and information services. The firm prefers to invest between $10 million to $250 million in equity per transactions. It invests generally between $1 million to $40 million in companies focused primarily on business services, communications, electronics, hardware, and healthcare services. The firm invests primarily in private companies but also have investments in public companies. For equity investments, the firm seeks to represent a controlling interest in its portfolio companies which may exceed 25% of the voting securities of such companies. The firm seeks to invest a limited portion of its assets in equipment-based loans to early-stage prospective portfolio companies. These loans are generally for amounts up to $3 million but may be up to $15 million for certain energy technology venture investments. The firm allows certain debt investments have the right to convert a portion of the debt investment into equity. It also co-invests with other private equity firms. The firm seeks to exit its investments through initial public offering, a private sale of equity interest to a third party, a merger or an acquisition of the company or a purchase of the equity position by the company or one of its stockholders. The firm has structured debt with warrants which typically have maturities of between two and seven years with an average of three years; senior debt with an investment horizon of less than three years; equipment loans with an investment horizon ranging from three to four years; and equity related securities with an investment horizon ranging from three to seven years. The firm prefers to invest through its balance sheet capital. The firm formerly known as Hercules Technology Growth Capital, Inc. Hercules Capital, Inc. was founded in December 2003 and is based in Palo Alto, California with additional offices in Connecticut; Boston, Massachusetts; San Diego, California; Westport, Connecticut; Elmhurst, Illinois; Santa Monica, California; McLean, Virginia; New York, New York; Radnor, Pennsylvania; and Washington, District of Columbia and London, United Kingdom.
Contact
400 Hamilton Avenue, Palo Alto, CA, 94301
https://www.htgc.com
IPO
Date
June 9, 2005
Employees
100
Officers
Ms. Kiersten Zaza Botelho
Corporate Secretary, Chief Legal & Compliance Officer
Mr. Michael Bowden
Managing Director of Portfolio Management
Mr. Michael W. Hara
Managing Director of Investor Relations & Corporate Communications
Ms. Kate Kinlin
Vice President of Human Resources
Mr. Roy Y. Liu
Managing Director
Mr. Scott Bluestein
Chief Executive Officer, Chief Investment Officer, President & Director
Mr. Seth Hardy Meyer
Chief Financial Officer & Chief Accounting Officer
Mr. R. Bryan Jadot
Senior MD & Group Head of Life Sciences
Mr. Christian Follmann
Chief Operating Officer
Mr. Steve Kuo
Senior MD & Group Head of Technology